In Vivo Validation of High-Throughput Drug Screen Results for NF2
Abstract
Neurofibromatosis type 2 (NF2) is a tumor disorder of the nervous system for which there is no drug therapy. Results of our drug screening campaigns revealed that two Food and Drug Administration-approved drugs reduced the viability of NF2 mutant mouse Schwann cells. Here we will profile the "best in class" SRC and MEK kinase inhibitors for efficacy in reducing viability of both mouse and our newly created human merlin-null Schwann cells. The best performing compounds will be evaluated in two animal models for NF2 schwannomas. Lastly, molecular studies will be conducted to compare treated and untreated mouse and human merlin-null Schwann cells to understand the pathways contributing to the drug responses. The outcome of this project will be to identify one or two compounds that could be advanced to clinical trials for NF2 and information that will guide future combination drug studies.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Apr 04, 2016
- Source ID
- W81XWH1510446
Entities
People
- Cristina Fernandez-valle
Organizations
- United States Army
- University of Central Florida